Member Info for Celtic007

Ten pence is the minium as it's a bargain given chk1 as a combo potential of fast track and the only tyk2 available described as best in class

Yes but the combined effect is very good or even the triple regimen.....chk1 is a great drug when combined and only one available in a hard to treat disease

OK so triple therapy still amazing ....if only indicated for these three conditions any one have a guess at price of share?

Hope their price keeps going down....make them think hard for their next step ...

Surely CRT will not be wanting this mothballed and Sar suffering as a result ... not fair .. .need CRT coming out and being very clear to siera that either pay up or sell it or give it back...how long can they mess us about? Are CRT and sar not legally able to take it back without counter law suit?

Exactly belhus...no other reason why they would buy these shares .. if sareum was a character in batman, it be the riddler lol

Hi thoth and all. After this week's data on our tyk 2 molecule are you ever more optimistic that this will blow once you add in tyk2 immune and the already more advanced chk1?

If these two molecules are best in class then surely 800m is pennies to a GSk or pfizer. The longer they hesitate then value keeps going up and possibly more interested parties become aware creating bidding war. Views please

So did this fail after they paid 2 billion to buy it? Wonder why so hard to treat this condition?

Thank you ...

Silly question. ..relevance to us ....?

Hi thoth. Is that a good success rate of 25 percent. ...how much of a market could we get with that? Hopefully this alone can get to 10p on this indication without combo.

Agree but you cannot deny science. . I am happy for ssra to go down the hole ...we get back our drug and our share goes up or they sell this onto partner and we get out share of royalties. ..win win win or win win . .let's see

Hi minden. The 10p share should be achievable on chk1 combo for a no genital alone as very good chance will get fast tracked . Any more combo for other indications and price goes up accordingly. As thoth said this data looks very good and we are the only available chk1 agent available. ...says a lot when all others failed. ..we succeeded ....the science is amazing. ..just needs someone good at building big deals

Thanks stoney....also it could be a unique moment in cancer research ...companies combining combinations and collaborating together to defeat this horrible disease. ...

Thanks thoth. So if we say that our chk1 is looking amazing in combo for anogenital and you think alone it is worth 10p...then if it is combined with other diseases and shows amazing results like small lung cancer then the 28p could be reached alone on this one drug.

And we still have not mentioned the big white elephant in the room that is tyk2 ...that is the one that could take this into orbit. Am I right in my summary or talking nonsense ? Thanks

Thanks stoney and thoth. Thoth,do you mean that our chk1 is only good going forward in combo not as single agent?

Lovely. ...so if they have already trialed our molecule and data looks good then it could be multiple uses and money money

Yes looks interesting ....is that for our chk1 ?

Thanks krone. Do you all still think that astra will take our chk1 for the triple therapy or could our chk1 be used in this combination therapy for anogenItal cancer?

Yes thoth.....I hope sierra is taken off the nasdeq and we can get out chk1 back....ito simple........pay us our payments due or tough....our board have surely got a few Brain cells there as not daft....no money coming in means more dilution at out expense ....no way ...enough is enough. ...just sell the lot for 5p